

DT02 Rec'd PCT/PTO 07 MAR 2005

PCT



Attorney Docket No. Le A 35 943

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Golz, et al.

Serial No.: 10/509,531

Filed: 09/22/2004

For: Diagnostics and Therapeutics for Diseases Associated with Growth Hormone Secretagogue Receptor (GHS)

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: MAR 04 2005

Jill Durante

MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office Action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Susan M. Pellegrino  
Attorney for Applicant(s)  
Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516

Reg. No.: 48,972

Telephone: (203) 812-6450

Date: MAR 04 2005

